The advent of the molecular world opening up for familial adenomatous polyposis and other genetically predisposed cancers has now provided us with wonderful tools to study these diseases. The challenges, however, clearly remain to transfer discoveries in the laboratory to improvements in the care of these patients.
INTRODUCTION
The Canadian Familial Adenomatous Polyposis (FAP) Registry, conceived and founded in 1980 by Dr Zane Cohen, serves as an exceptional example of the benefits to be obtained by, first, determining the nature of a clinical problem, second, meticulously cataloguing one's observations, and finally, directing all efforts at the bench and bedside to solving the problem. In Canada we have altered the natural history of familial adenomatous polyposis, prevented premature deaths from colorectal cancer, and continue to contribute to the fundamental body of knowled~of the genes and environmental influences that control it 1 \ 9 . Current and future efforts will be aimed at determining whether the benefits obtained from the establishment of an FAP registry can be extended to other hereditary cancer syndromes and possibly even sporadic colorectal cancer.
THE PAST
The Canadian FAP Registry was initially established as the Province of Ontario Registry in 1980 at the Toronto General Hospital. The first step was to develop an organizational structure on the St Mark's model. The work included recording pedigrees, coordinating screening and cataloguing all records; and generally caring for patients. All pathology records were kept under the supervision of a single pathologist.
Initial research efforts reflected the nature of our understanding of the disease at that time, and publications in the first years were directed at reVieWing the effects of registration on prevention of premature deaths from colorectal cancer. Subsequent research efforts were directed at the establishment of improved markers for detection of the disease", as well as assessing the effects of dietary interventions on colonic proliferation indices 7 . In the latter publication, the authors demonstrated that dietary calcium appeared to have no protective effect on colon cancer risk in a cohort of FAP patients. Additionally, it was of great benefit to be able to study a relatively homogeneous population over a period of 9 months 7 .
THE PRESENT
Studies of the psycho-social impact of the disease and the development of strategies to assist these patients to cope with the disease began early in the registry's history but legitimately belong in all three phases of past, present and future. Research into psychosocial areas resulted in the development of patient aids, currently used internationally, and published work indicating the scope and depth of these areas''.
The discovery of the APC gene led us to establish a diagnostiC and research DNA laboratory for the registry. This brought us into the molecular world and has created the focus for our latest research efforts1-3. We have sequentially assessed APC mutations in periampullary tumours, examined, the benefits of combinations of biological and molecular markers in FAP screening, and defined two novel APC mutations.
Nevertheless we have not lost sight of the needs to continuously re-examine our patients in an effort to transfer our knowledge into better management. Whereas we may have reduced premature colorectal cancer deaths, patients are still dying from extra-colonic manifestations of FAP such as desmoid tumours. We have documented our surgical failures in these tumours and reviewed our current management with the combined use of NSAIDs and tamoxifen''.
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Finally, we are examining the mechanisms by which we screen patients and are now changing from the more morbid sigmoidoscopic!colonoscopic route to direct mutational analysis, a clear example of bench to bedside progress.
THE FUTURE
The discovery of genes linked to hereditary non-polyposis colorectal cancer has heightened awareness of the genetic controls of colorectal cancer in generaPo. We in Canada have made the conscious decision to coordinate our efforts in all forms of hereditary colon cancer into what are now being termed hereditary GI cancer registries. Additionally, the cancer control agency of the Province of Ontario (Ontario Cancer Treatment and Research Foundation) has begun an initiative to study as a pilot project the impact of a coordinated network of five regional centres in the province on not only genetically predisposed colon cancers but breast, ovary and uterine cancer as well. The Toronto-based Hereditary GI Cancer Registry and the Ottawa Regional GI Cancer Registry have made great strides in linking colorectal cancer efforts and are helping the other three centres develop the modelrs) for breast!ovary cancer registries.
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